External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>The company’s sales increased by 20.2% YoY to Rs 5,197 Cr, and the growth was majorly led by its US business of $212 (+0.5% Q0Q).</li><li>The US sales continue to see encouraging traction in sales of gSuperb, gAlbuterol, gLisinopril, and new launches Darunivar (exclusivity in 800 mg) and gSpiriva (32% Market Share in the last 5 months) while the base business experienced low single-digit price erosion.</li><li>The India business (+13.4% YoY) outperformed IPM growth in key therapies such as CVS and anti-diabetic. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

The company’s sales increased by 20.2% YoY to Rs 5,197 Cr, and the growth was majorly led by its US business of $212 (+0.5% Q0Q).The US sales continue to see encouraging traction in sales of gSuperb, gAlbuterol, gLisinopril, and new launches Darunivar (exclusivity in 800 mg) and gSpiriva (32% Market Share in the last 5 months) while the base business experienced low single-digit price erosion.The India business (+13.4% YoY) outperformed IPM growth in key therapies such as CVS and anti-diabetic. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Lupin Ltd

LUPIN Ltd - Margins Guidance Increased